产品
编 号：F253777
分子式：C27H37N3O7S
分子量：547.66
分子式：C27H37N3O7S
分子量：547.66
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
320
In-stock
10mg
480
In-stock
25mg
720
In-stock
50mg
1120
In-stock
结构图
CAS No: 206361-99-1
产品详情
生物活性：
Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity.
体外研究：
Darunavir (TMC114, 1a) has a stability comparable to other protease inhibitors.Darunavir (TMC114, UIC-94017) blocks the infectivity and replication of each of HIV-1NL4-3 variants exposed to and selected for resistance to Ro 31-8959, MK-639, AG1341, or ABT 538 at concentrations up to 5 μM (IC50s, 0.003 to 0.029 μM), although it was less active against HIV-1NL4-3 variants selected for resistance to VX-478 (IC50, 0.22 μM).
Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity.
体外研究：
Darunavir (TMC114, 1a) has a stability comparable to other protease inhibitors.Darunavir (TMC114, UIC-94017) blocks the infectivity and replication of each of HIV-1NL4-3 variants exposed to and selected for resistance to Ro 31-8959, MK-639, AG1341, or ABT 538 at concentrations up to 5 μM (IC50s, 0.003 to 0.029 μM), although it was less active against HIV-1NL4-3 variants selected for resistance to VX-478 (IC50, 0.22 μM).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备